Barclays PLC Vanda Pharmaceuticals Inc. Transaction History

Barclays PLC

$436 Billion
Q2 2025

A detailed history of Barclays PLC transactions in Vanda Pharmaceuticals Inc. stock. As of the latest transaction made, Barclays PLC holds 224,404 shares of VNDA stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

224,404

Previous 224,404 -0.0%

Holding current value

$1.2 Million

Previous $1.06 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 13, 2025	BUY	$3.92 - $4.82 $220,739 - $271,419	56,311 Added 33.5%	224,404 $1.06 Million
Q1 2025 May 15, 2025	SELL	$4.31 - $5.13 $44,285 - $52,710	-10,275 Reduced 5.76%	168,093 $771,000
Q4 2024 Feb 13, 2025	BUY	$4.41 - $5.46 $106,153 - $131,427	24,071 Added 15.6%	178,368 $854,000
Q3 2024 Nov 15, 2024	BUY	$4.61 - $6.34 $399,580 - $549,532	86,677 Added 128.18%	154,297 $722,000
Q2 2024 Aug 14, 2024	SELL	$3.91 - $6.5 $226,998 - $377,364	-58,056 Reduced 46.19%	67,620 $382,000
Q1 2024 May 15, 2024	SELL	$3.47 - $4.61 $159,488 - $211,884	-45,962 Reduced 26.78%	125,676 $516,000
Q4 2023 Feb 15, 2024	BUY	$3.38 - $4.58 $146,381 - $198,350	43,308 Added 33.75%	171,638 $725,000
Q3 2023 Nov 07, 2023	BUY	$4.28 - $6.57 $13,974 - $21,451	3,265 Added 2.61%	128,330 $554,000
Q2 2023 Aug 03, 2023	BUY	$5.9 - $6.95 $146,148 - $172,158	24,771 Added 24.7%	125,065 $824,000
Q1 2023 May 04, 2023	BUY	$6.18 - $7.99 $21,939 - $28,364	3,550 Added 3.67%	100,294 $682,000
Q4 2022 Feb 13, 2023	SELL	$6.87 - $10.96 $17,573 - $28,035	-2,558 Reduced 2.58%	96,744 $716,000
Q3 2022 Nov 03, 2022	BUY	$9.44 - $11.76 $765,055 - $953,077	81,044 Added 443.88%	99,302 $981,000
Q2 2022 Aug 12, 2022	SELL	$9.31 - $11.84 $246,817 - $313,890	-26,511 Reduced 59.22%	18,258 $199,000
Q1 2022 May 16, 2022	SELL	$10.84 - $16.55 $291,292 - $444,731	-26,872 Reduced 37.51%	44,769 $507,000
Q4 2021 Feb 14, 2022	BUY	$15.69 - $21.14 $232,823 - $313,696	14,839 Added 26.12%	71,641 $1.12 Million
Q3 2021 Nov 09, 2021	BUY	$15.35 - $21.27 $351,699 - $487,338	22,912 Added 67.61%	56,802 $974,000
Q2 2021 Aug 13, 2021	SELL	$15.71 - $21.51 $1 Million - $1.37 Million	-63,808 Reduced 65.31%	33,890 $729,000
Q1 2021 May 13, 2021	BUY	$13.42 - $20.28 $205,446 - $310,466	15,309 Added 18.58%	97,698 $1.47 Million
Q4 2020 Feb 11, 2021	SELL	$9.77 - $13.81 $243,468 - $344,145	-24,920 Reduced 23.22%	82,389 $1.08 Million
Q3 2020 Nov 12, 2020	BUY	$9.32 - $12.02 $95,716 - $123,445	10,270 Added 10.58%	107,309 $1.04 Million
Q2 2020 Aug 12, 2020	BUY	$9.66 - $12.02 $228,845 - $284,753	23,690 Added 32.3%	97,039 $1.11 Million
Q1 2020 May 13, 2020	SELL	$7.5 - $16.8 $123,315 - $276,225	-16,442 Reduced 18.31%	73,349 $760,000
Q4 2019 Feb 10, 2020	BUY	$12.38 - $17.47 $175,981 - $248,336	14,215 Added 18.81%	89,791 $1.47 Million
Q3 2019 Nov 14, 2019	SELL	$12.27 - $15.79 $184,553 - $237,497	-15,041 Reduced 16.6%	75,576 $1 Million
Q2 2019 Aug 14, 2019	BUY	$13.37 - $18.85 $309,221 - $435,962	23,128 Added 34.27%	90,617 $1.28 Million
Q1 2019 May 15, 2019	BUY	$17.59 - $31.05 $769,632 - $1.36 Million	43,754 Added 184.34%	67,489 $1.24 Million
Q4 2018 Feb 14, 2019	SELL	$18.97 - $31.47 $787,198 - $1.31 Million	-41,497 Reduced 63.61%	23,735 $620,000
Q3 2018 Nov 14, 2018	BUY	$18.25 - $23.0 $1.07 Million - $1.35 Million	58,631 Added 888.21%	65,232 $1.5 Million
Q2 2018 Aug 14, 2018	SELL	$13.95 - $19.15 $253,150 - $347,515	-18,147 Reduced 73.33%	6,601 $126,000
Q1 2018 May 15, 2018	BUY	$14.05 - $20.2 $167,195 - $240,380	11,900 Added 92.62%	24,748 $417,000
Q4 2017 Feb 14, 2018	SELL	$12.85 - $18.1 $474,679 - $668,614	-36,940 Reduced 74.19%	12,848 $195,000
Q3 2017 Nov 14, 2017	BUY	$15.4 - $18.85 $766,735 - $938,503	49,788	49,788 $891,000

Others Institutions Holding VNDA

# of Institutions

150

Shares Held

45.3M

Call Options Held

20K

Put Options Held

999K

View Full List

About Vanda Pharmaceuticals Inc.

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $301M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

More about VNDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account